Devices, digital health, and the technology changing how care is delivered.
New 3D printed technology makes lower extremity surgeons architects of restoration, not adaptation. The post Why Settle for Acceptable Versus Optimal Outcomes? appeared first on MedCity News .
Another biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Therapeutics, a San Diego-based oncology outfit focused on small molecules, has filed paperwork with the Securities and Exchange Commission to publicly offer stock for the first time.
Boston. San Francisco. Beijing? The global biotech industry has long been concentrated in a handful of cities. But which emerging hubs could become dominant forces in biotech in the decades ahead?
Abbott turned in a stronger-than-expected second quarter, allaying market concerns that subsidy cuts to the Affordable Care Act by the Trump administration would hurt medtech firms.
Biotronik Neuro has acquired a portfolio of spinal cord stimulation patents from the Ohio-based medical device company Soin Neuroscience as the pair look to create “a next-generation spinal cord stimulation program.”
DePuy expects the technology, which doesn’t use screws, will strengthen its spine business and integrate into its Velys portfolio.
In this episode, ACC Chief Innovation Officer Dr. Ami Bhatt speaks with Dr. Krishna Pundi about how digital health tools and wearable technologies are helping to manage cardiovascular risk and chronic arrhythmias in patients.
The Exact Sciences acquisition, which closed in March, fueled more than 40% growth in Abbott’s diagnostics sales in the second quarter.
A string of recent wins on the frontiers of novel drug development could mean that a homegrown innovation industry is within reach.
Cue Biopharma is tapping in a new chief medical officer and head of R&D in Dominic Borie, M.D., Ph.D., a physician-scientist with over two decades of industry experience.
This is not an argument against capital in independent medicine. Practices need infrastructure, and physicians have legitimate reasons to seek liquidity. It is an argument that the exit stage carries a risk this market has not yet priced. The post What Happens to Independent Medicine When Private Equity Shows Up With a Checkbook appeared first on MedCity News .
Chintan Desai, formerly of Alcon and GE HealthCare, has experience leading medtech teams in the region.
If we do not get this right, we may inadvertently cause a new sarcopenia epidemic while congratulating ourselves on solving obesity. The post GLP-1s Are Working — Now Medicine Needs to Measure What Matters appeared first on MedCity News .
For years, the healthcare industry treated data collection as the main challenge. The next phase is about interpretation, coordination, and operational usability. The post Building AI-Ready Public Health Data Systems for Faster, Safer Decisions appeared first on MedCity News .
Eli Lilly has struck a deal to buy AtaiBeckley for $2.8 billion upfront, continuing its takeover spree to move into a psychedelic mental health sector targeted by companies including Johnson & Johnson.
This cross-sectional study examines associations between digital health engagement within clinical care systems and psychological distress among US adults.
Digital health funding hit $7.4 billion in the first half of 2026, with megadeals absorbing nearly half of all capital. As AI becomes table stakes, founders and investors say the real differentiator is now domain expertise rather than technology. The post ‘The Moat is No Longer Technological’: How Digital Health Fundraising Changed in H1 appeared first on MedCity News .
Neko’s Series C round was co-led by Lightspeed Venture Partners and O.G. Venture Partners, with participation from Atomico, General Catalyst, Lakestar, Liberty City Ventures, Positive Sum and BDT & MSD. The post Neko Health Secures $700M to Support US Expansion appeared first on MedCity News .
The robot developer’s board set a July 21 date for shareholders to vote on a proposal to wind down operations amid expectations for continued operating losses.
Jorge Garces, who joined Abbott to oversee scientific strategy for cancer diagnostics after it acquired Exact Sciences, discusses the future of the field.
Sales in Johnson & Johnson’s Abiomed business declined in the second quarter due to procedure volume pressures related to its Impella device.
Jennifer Doudna, Ph.D., the Nobel Laureate best known for co-inventing the CRISPR system that has become the foundation for gene-editing, is dipping her toes into a new, buzzy field: AI-powered protein design.
Lonza explains why early de-risking has become a strategic imperative for biotech teams working to reach IND with confidence.
Earlier this year, my colleague Matt Harrington suggested that clinical leaders should stop asking whether their organizations have an “AI strategy”, not because strategy doesn’t matter, but because the question often produces the wrong conversation.